Peter A. Thompson
CIK 1357522 · Interim Chief Exec Officer · last filed 2026-07-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SION price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
54TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SION | Director | 2,469,959 | $3.84 | $9.48M | -$45.77M | 13 | 2026-07-09 |
| SPRY | Director | 269,323 | $3.69 | $992.5K | -$9.49M | 7 | 2026-06-26 |
| EWTX | Director | 443,792 | $39.51 | $17.53M | $26.74M | 10 | 2026-06-17 |
| CRVS | Director | 8,684,091 | $10.54 | $91.53M | $10.58M | 30 | 2026-06-15 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 0 | $64.97 | $0 | -$25.72M | 14 | 2024-05-20 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 327,852 | $4.91 | $1.61M | $30.00M | 3 | 2022-06-21 |
| JANX | Director | 231,098 | $17.16 | $3.97M | $1.41M | 6 | 2022-06-16 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | Director | 952,377 | $5.87 | $5.59M | $25.00M | 4 | 2022-06-13 |
| PMVP | Director | 114,039 | $1.24 | $140.8K | $17.10M | 2 | 2021-06-09 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | 12,940,111 | — | — | $15.00M | 2 | 2020-06-19 |
| THOR | Director | 0 | $25.55 | $0 | $15.00M | 4 | 2020-01-24 |
| ASND | Director | 4,902,910 | $245.40 | $1.20B | $8.09M | 8 | 2018-06-06 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,989,949 | — | — | $2.98M | 1 | 2015-07-21 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | — | — | — | $0 | 2 | 2012-05-10 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | President and CEO | 386,419 | — | — | $50.3K | 5 | 2009-08-28 |
Recent Filings · Page 10 of 13
128 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-07-26 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | +3,298,516 | $0 | EDGAR |
| 2017-07-03 | ASND | Grant (A) | — | $0 | EDGAR |
| 2017-06-09 | CRVS | Grant (A) | — | $0 | EDGAR |
| 2017-03-28 | ASND | Buy (P) | +1,190,476 | $5.00M | EDGAR |
| 2016-12-01 | — | Mixed | −5,885,343 | $0 | |
| 2016-08-12 | ASND | Grant (A) | — | $0 | EDGAR |
| 2016-06-27 | CRVS | Buy (P) | +1,000 | $13.0K | EDGAR |
| 2016-06-21 | CRVS | Buy (P) | +38,383 | $489.2K | EDGAR |
| 2016-06-20 | — | Buy (P) | +892,858 | $500.0K | |
| 2016-06-16 | CRVS | Buy (P) | +20,000 | $247.0K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.